Adverum Biotechnologies I...

2.93
-0.05 (-1.68%)
At close: Apr 17, 2025, 3:59 PM
2.93
0.00%
After-hours: Apr 17, 2025, 04:05 PM EDT
-1.68%
Bid 2.8
Market Cap 61.21M
Revenue (ttm) -2.6M
Net Income (ttm) -130.93M
EPS (ttm) -6.62
PE Ratio (ttm) -0.44
Forward PE -0.71
Analyst Buy
Ask 3.35
Volume 285,190
Avg. Volume (20D) 173,324
Open 2.94
Previous Close 2.98
Day's Range 2.75 - 2.98
52-Week Range 2.75 - 11.87
Beta 1.09

About ADVM

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with U...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 155
Stock Exchange NASDAQ
Ticker Symbol ADVM
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 923.89% from the latest price.

Stock Forecasts

Earnings Surprise

Adverum Biotechnologies has released their quartely earnings on Apr 15, 2025:
  • Revenue of $0 misses estimates by $100K, with NaN% YoY growth.
  • EPS of -1.96 misses estimates by -0.58, with 14.78% YoY growth.